Immunic, Inc. Files Form 8-K

Ticker: IMUX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1280776

Immunic, INC. 8-K Filing Summary
FieldDetail
CompanyImmunic, INC. (IMUX)
Form Type8-K
Filed DateJan 13, 2025
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: event-report, 8-K

Related Tickers: IMUX

TL;DR

IMUX filed an 8-K on Jan 13, 2025, but didn't say why. Need more info.

AI Summary

On January 13, 2025, Immunic, Inc. reported an event under Item 8.01 of its Form 8-K. The filing does not contain specific details about the nature of the event, only that it occurred on this date and is being reported by the company.

Why It Matters

This filing indicates Immunic, Inc. is reporting a significant event, but the lack of detail requires further investigation to understand its implications.

Risk Assessment

Risk Level: medium — The filing is a standard 8-K reporting an event, but the lack of specific details about the event itself introduces uncertainty.

Key Players & Entities

FAQ

What specific event is Immunic, Inc. reporting on January 13, 2025?

The provided text of the 8-K filing does not specify the nature of the event reported on January 13, 2025, only that an event occurred and is being reported under Item 8.01.

What is the purpose of an 8-K filing?

An 8-K filing is a report of "unscheduled material events or corporate changes" that could be of importance to investors.

What is Immunic, Inc.'s trading symbol?

Immunic, Inc.'s common stock trades on the Nasdaq under the symbol IMUX.

What jurisdiction is Immunic, Inc. incorporated in?

Immunic, Inc. is incorporated in Delaware.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 13, 2025.

Filing Stats: 1,083 words · 4 min read · ~4 pages · Grade level 14.8 · Accepted 2025-01-13 08:32:07

Key Financial Figures

Filing Documents

01. Other Events

Item 8.01. Other Events. On January 13, 2025, Immunic, Inc. (the " Company ") posted an updated presentation (the " Presentation ") on its website, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 8.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein. Cautionary Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K and the Presentation are "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Current Report on Form 8-K and the Presentation regarding new management hires and promotions, strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; announcments regarding the positive outcomes of the interim analysis of the phase 3 ENSURE trials; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of th

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit Description 99.1 Presentation, dated January 13, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: January 13, 2025 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing